Market Overview

Tourette Syndrome | A Drug Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest pipeline analysis report on the
drug pipeline for Tourette
syndrome
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat Tourette syndrome.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180813005302/en/

Technavio has published a new report on the drug development pipeline for Tourette syndrome, includi ...

Technavio has published a new report on the drug development pipeline for Tourette syndrome, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Tourette syndrome: Market overview

Tourette syndrome is named after Dr. Georges Gilles de la Tourette. It
is defined as a neurological disorder characterized by repetitive,
sudden, and involuntary movements or noises called tics due to the
mutations of the SLITRK1 gene. SLITRK1 plays an important role in the
development of nerve cells. It involves four types of tics, namely motor
tics (uncontrolled body movements), vocal tics (outburst of sound),
simple tics (involves few parts of the body), and complex tics (involves
several parts of the body). In addition, people with Tourette syndrome
are at the risk of attention-deficit/hyperactivity disorder (ADHD),
obsessive-compulsive disorder (OCD), anxiety, depression, and
sleep-related problems. It starts between the age of 3 and 9, and it
spreads over a period of time. Males are more vulnerable to Tourette
syndrome compared with females.

According to a senior market research analyst at Technavio, "As per
National Institutes of Health, it is estimated that 1 to 10 in 1,000
children are affected by Tourette syndrome globally. As per the 2018
report of the Centers for Disease Control and Prevention, 0.3% of the
children in the US are diagnosed with Tourette syndrome."

Tourette syndrome: Segmentation analysis

This pipeline analysis report segments the Tourette syndrome market
based on therapies employed (monotherapy and combination therapy), RoA
(oral and transdermal), therapeutic modality (small molecule), targets
(VMAT2, GABA-AT, cannabinoid receptor, cannabinoid receptor CB1,
dopamine D1 receptor, and dopamine-serotonin), MoA (VMAT2 inhibitor,
GABA-AT inhibitor, cannabinoid receptor activator, cannabinoid receptor
CB1 agonist, cannabinoid receptor stimulator, dopamine D1 receptor
antagonist, and dopamine-serotonin stabilizer), geographical
segmentation (US, Germany, and Puerto Rico), and recruitment status
(active, not recruiting, completed, not yet recruiting, and recruiting).
It provides an in-depth analysis of the prominent factors influencing
the market, including drivers, opportunities, trends, and
industry-specific challenges.

Based on the route of administration, more than 58% of the molecules are
being investigated for the treatment of Tourette syndrome are
administered through oral medications.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!